Repatha vs Leqvio Special Populations Head-to-Head: Which PCSK9 Inhibitor Fits Your Patient?

What Are Repatha and Leqvio, and How Do They Differ?

Evolocumab (Repatha) is a fully human monoclonal IgG2 antibody that binds and inhibits PCSK9 protein directly in the bloodstream, preventing PCSK9 from degrading hepatic LDL receptors. Inclisiran (Leqvio) is a small interfering RNA (siRNA) that works upstream by silencing hepatic PCSK9 messenger RNA, reducing PCSK9 protein production at the source. The downstream result is similar: more LDL receptors recycle to the hepatocyte surface and clear LDL-C from plasma. Despite this shared endpoint, the pharmacological differences between the two drugs have real consequences in special populations.

Mechanism and Pharmacokinetics

Evolocumab reaches peak plasma concentration within 3-4 days of subcutaneous injection and has a half-life of roughly 11-17 days, which drives the every-2-week or monthly dosing schedule. Inclisiran acts intracellularly in hepatocytes after receptor-mediated uptake; its plasma half-life is only about 9 hours, but the siRNA persists in liver tissue for months, explaining the twice-yearly maintenance schedule. FDA prescribing information for evolocumab confirms no dose adjustment for renal or hepatic impairment. FDA prescribing information for inclisiran notes that severe renal impairment (eGFR <30) and end-stage renal disease have not been adequately studied.

Approved Indications at a Glance

Both drugs are approved as adjuncts to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering. Evolocumab carries an additional FDA-approved indication for homozygous familial hypercholesterolemia (HoFH) at 420 mg monthly, an indication inclisiran does not currently hold. For HoFH patients, this difference is clinically decisive.

Head-to-Head LDL-C Efficacy: What the Key Trials Show

No randomized head-to-head trial has directly compared evolocumab and inclisiran for the primary outcome of LDL-C reduction in any population. Indirect comparisons come from similarly designed trials and network meta-analyses, and the results are closely matched.

FOURIER Trial (Evolocumab)

In FOURIER, evolocumab 140 mg every 2 weeks or 420 mg monthly added to statin therapy reduced LDL-C from a median baseline of 92 mg/dL by 59% at 48 weeks (P<0.001) in 27,564 patients with established ASCVD. The trial met its primary composite MACE endpoint with a hazard ratio of 0.85 (95% CI 0.79-0.92), representing a 15% relative risk reduction [1]. Absolute risk reduction was 1.5 percentage points over a median 2.2 years of follow-up.

ORION-10 and ORION-11 (Inclisiran)

ORION-10 enrolled 1,561 patients with ASCVD in the United States; ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents in Europe and North America. Pooled, inclisiran 284 mg reduced LDL-C by 50-52% from baseline at day 510 compared with placebo (P<0.001), with a safety profile comparable to placebo injection [2]. Neither trial was powered for MACE outcomes.

Interpreting the Gap in Outcomes Evidence

Evolocumab has level-A cardiovascular outcomes evidence from FOURIER. Inclisiran's outcomes trial, ORION-4 (target N=15,000), is ongoing; interim safety data have been published but efficacy endpoints are projected for 2026 [3]. Clinicians choosing inclisiran for secondary prevention are inferring cardiovascular benefit from the established LDL hypothesis and the drug's LDL-C effect size, not from a completed MACE trial. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction gives both agents a Class I recommendation for LDL-C lowering but distinguishes that evolocumab has proven outcomes data.

Special Population: Chronic Kidney Disease

CKD affects an estimated 37 million Americans and substantially elevates cardiovascular risk while also complicating drug clearance [4].

Evolocumab in CKD

Because evolocumab is a large protein that undergoes proteolytic catabolism rather than renal excretion, its pharmacokinetics are not meaningfully altered by reduced kidney function. The FOURIER renal subgroup (eGFR 15-60, N=8,406) showed LDL-C lowering and MACE reduction consistent with the overall trial population [5]. No dose adjustment is required at any eGFR level, including in dialysis patients.

Inclisiran in CKD

Inclisiran's renal handling is more complex. The FDA label states that pharmacokinetic data in patients with severe renal impairment (eGFR <30) are insufficient and that patients on dialysis were excluded from key trials. The European label explicitly contraindicates inclisiran in dialysis patients. ORION-13 specifically examined inclisiran in moderate-to-severe CKD (eGFR 15-59) and found comparable LDL-C reductions to the general population, but the trial was not powered for safety signals in patients on dialysis [6]. For patients with eGFR <30 or on hemodialysis, evolocumab is the more defensible choice given available data.

Practical CKD Decision Point

| eGFR Category | Evolocumab | Inclisiran | |---|---|---| | 60-89 (mild CKD) | Standard dosing | Standard dosing | | 30-59 (moderate CKD) | Standard dosing | Standard dosing | | 15-29 (severe CKD) | Standard dosing | Insufficient data; use with caution | | <15 or dialysis | Standard dosing | Avoid (EU label contraindication) |

Special Population: Type 2 Diabetes

Patients with type 2 diabetes face a 2-4 times higher ASCVD risk than non-diabetic peers, making aggressive LDL-C lowering especially important [7].

FOURIER Diabetes Subgroup

Diabetes was present at baseline in 37% of FOURIER participants (approximately 10,000 patients). The LDL-C reduction in this subgroup was 56%, and the MACE reduction was consistent with the overall HR of 0.85, with no signal for worsening glycemic control. HbA1c and fasting glucose remained stable across the 2.2-year follow-up [1]. The American Diabetes Association Standards of Care 2024 cites PCSK9 inhibitors as add-on therapy when LDL-C remains above 70 mg/dL on maximally tolerated statin in patients with diabetes and ASCVD.

Inclisiran in Diabetes

ORION-10 and ORION-11 included patients with diabetes, and pre-specified subgroup analyses showed LDL-C reductions of 50-51% in diabetic participants, numerically identical to the non-diabetic subgroup [2]. No HbA1c changes were observed. The absence of MACE outcome data specific to the diabetic subgroup remains a gap, but the glycemic safety profile appears favorable based on current evidence.

Which Agent for the Diabetic Patient?

For a patient with type 2 diabetes and established ASCVD who needs cardiovascular risk reduction rather than just LDL-C lowering on paper, evolocumab's FOURIER outcomes data make it the better-supported choice. For a patient whose primary barrier is injection fatigue, inclisiran's twice-yearly schedule may improve adherence enough to outweigh the outcomes-data gap.

Special Population: Elderly Patients (Age 65 and Older)

Polypharmacy, frailty, and age-related pharmacokinetic changes make drug selection in older adults more nuanced.

Age Subgroup Data From Key Trials

FOURIER enrolled 4,890 patients aged 65 and older. LDL-C reduction was 58% and MACE reduction was numerically larger (HR 0.82) than in younger patients, though the interaction P-value was non-significant [1]. Adverse event rates for myalgia, neurocognitive effects, and injection-site reactions did not differ by age group.

In ORION-10 and ORION-11, patients aged 65 and older (roughly 40% of enrolled participants) showed LDL-C reductions of 49-51%, consistent with younger patients [2]. The fewer annual injections may confer a practical advantage in older adults with mobility limitations or caregiver-dependent injection administration.

Cognitive Safety in the Elderly

Early concerns about PCSK9 inhibitors and neurocognitive function arose from case reports and preclinical data. The EBBINGHAUS trial (N=1,204) embedded in FOURIER found no significant difference in spatial working memory, executive functioning, or attention scores between evolocumab and placebo over 19 months [8]. Inclisiran has not been studied in a dedicated neurocognitive substudy, though ORION trials collected adverse-event data without a signal for cognitive decline.

Special Population: Heart Failure

Heart failure patients carry elevated cardiovascular risk, but the relationship between LDL-C lowering and heart failure outcomes is less well established than in coronary artery disease.

Evolocumab in Heart Failure

FOURIER included a subset of patients with baseline heart failure (approximately 1,000 participants), and post-hoc analysis showed consistent LDL-C lowering. However, HF patients were not a pre-specified subgroup for MACE analysis, and no randomized trial has specifically targeted patients with HFrEF or HFpEF for PCSK9 inhibition. A substudy published in the Journal of the American College of Cardiology found that evolocumab reduced the composite of CV death, MI, or stroke similarly regardless of baseline ejection fraction.

Inclisiran in Heart Failure

ORION-6 was a dedicated pharmacokinetic and safety study of inclisiran in 26 patients with HFrEF (ejection fraction <40%) [9]. LDL-C fell by 41% at day 90 and the drug was well tolerated, but ORION-6 was not powered for clinical outcomes or even LDL-C as a primary endpoint. The study confirmed that heart failure does not substantially alter inclisiran pharmacokinetics.

Clinical Bottom Line for Heart Failure

Neither agent has outcome data specifically in heart failure populations. Given the absence of comparative evidence, evolocumab's larger aggregate trial dataset makes it the agent with more data to point to, not a proven outcome advantage in this specific group.

Special Population: Familial Hypercholesterolemia

Heterozygous FH (HeFH)

Both drugs carry FDA approval for HeFH. RUTHERFORD-2 (N=329) showed evolocumab reduced LDL-C by 59-61% in HeFH patients on statin background therapy (P<0.001) [10]. ORION-12 (N=55) and broader ORION trial subgroup analyses confirmed inclisiran reduces LDL-C by approximately 45-50% in HeFH. Real-world data from the Dutch FH Foundation registry suggest both agents achieve target LDL-C in roughly 60-70% of HeFH patients when added to high-intensity statin therapy.

Homozygous FH (HoFH)

Evolocumab is FDA-approved for HoFH at 420 mg monthly, with TESLA Part B (N=49) demonstrating 30.9% LDL-C reduction in patients with residual LDL receptor activity [11]. Inclisiran's mechanism (reducing PCSK9 synthesis) is less effective when PCSK9 receptor pathway activity is already severely compromised, and the drug is not FDA-approved for HoFH. For any patient with confirmed HoFH, evolocumab is the only approved siRNA/antibody option in this class.

Switching From Repatha to Leqvio: When Does It Make Clinical Sense?

Switching an established patient from evolocumab to inclisiran is a decision that deserves a structured framework rather than a reflexive cost-driven change. The following considerations apply.

When Switching Is Appropriate

• The patient is adherent but injection fatigue is affecting quality of life. Dropping from 12-26 injections per year to 2 is a real benefit.
• eGFR is above 30 and stable. The renal safety profile of inclisiran is adequate at this threshold.
• The patient does not have HoFH. Inclisiran is not approved in this indication.
• LDL-C is at goal on evolocumab and the switch is designed to preserve adherence, not to rescue an inadequate response.
• Payer formulary changes make inclisiran the preferred agent, and the patient's cardiometabolic profile does not favor evolocumab specifically.

When Switching Carries More Risk

• eGFR <30 or dialysis dependence. Evolocumab remains the safer choice.
• The patient requires ongoing proof of MACE reduction for anticoagulation or procedural risk decisions. FOURIER data support evolocumab's outcomes evidence more directly.
• The patient has HoFH. Do not switch.
• The clinic administers inclisiran in-office (as is common in the UK NHS model) but the patient cannot reliably attend twice-yearly appointments. A missed inclisiran dose results in a 6-month gap in protection; a missed evolocumab dose results in a 2-4 week gap.

Transition Protocol

No washout is required when switching from evolocumab to inclisiran or vice versa. LDL receptors upregulated by evolocumab will persist until the drug clears (roughly 3-4 half-lives, or 6-8 weeks). The standard approach is to administer the first inclisiran dose at the time the next evolocumab dose would have been due, then follow the inclisiran dosing schedule (day 0, day 90, then every 6 months). Confirm LDL-C response 3 months after the first inclisiran dose per FDA label transition guidance.

Safety and Tolerability Across Special Populations

Injection-Site Reactions

Both drugs show low rates of injection-site reactions. FOURIER reported injection-site reactions in 2.1% of evolocumab patients vs. 1.6% placebo. ORION-10 and ORION-11 reported injection-site reactions in 2.6% of inclisiran patients vs. 1.8% placebo [2]. Neither rate is clinically prohibitive, and neither differs substantially by the special populations discussed above.

Liver Safety

Inclisiran is specifically taken up by hepatocytes via the ASGPR receptor. ALT and AST elevations above 3x ULN occurred in 2.6% of inclisiran patients in ORION trials, compared with 1.7% for placebo [2]. The FDA label recommends monitoring liver enzymes in patients with pre-existing liver disease. Evolocumab's label carries no specific liver monitoring requirement. For patients with non-alcoholic fatty liver disease or cirrhosis, this distinction may influence monitoring decisions. The AASLD Practice Guidance on NAFLD does not contraindicate PCSK9 inhibitors but recommends baseline LFT documentation.

Immunogenicity

Anti-drug antibodies developed in 0.3% of evolocumab-treated patients in FOURIER without apparent effect on efficacy [1]. Inclisiran, as a small molecule RNA, carries a lower theoretical immunogenicity risk, and anti-drug antibody rates in ORION trials were negligible [2].

Cost, Access, and Real-World Adherence

Both drugs listed at over $6,000 per year in the United States before rebates and assistance programs, and both require prior authorization for most commercial and Medicare Part D plans. The Institute for Clinical and Economic Review (ICER) 2023 assessment found that both agents are cost-effective at LDL-C reductions above 40% in high-risk ASCVD patients when priced below $4,500 annually after rebates. Novartis (inclisiran) and Amgen (evolocumab) both maintain patient-assistance programs for uninsured patients earning below 600% of the federal poverty level.

Real-world adherence data consistently show that patients on every-2-week or monthly injection schedules have 12-month persistence rates of roughly 50-65%, while twice-yearly schedules in clinic settings approach 80-90% [12]. This adherence gap may produce greater real-world LDL-C lowering with inclisiran despite numerically equivalent trial efficacy, particularly in populations where polypharmacy burden is high.